Gender-affirming estrogen therapy and breast cancer treatment outcome

性别肯定雌激素治疗和乳腺癌治疗结果

基本信息

  • 批准号:
    10350731
  • 负责人:
  • 金额:
    $ 24.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-12-21 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary Our overall objectives in this proposal are to establish a cross-sex mouse model for breast cancer (BC) and develop BC treatment strategies for transfeminine individuals receiving estrogen therapy (ET). Transfeminine individuals are assigned male at birth and a majority of them pursue ET to affirm their feminine identity. Exposing the male body to extremely high exogenous estrogen over extended periods in order to achieve levels comparable to cisgender women raises concerns about the adverse effects of ET. ET is essential for their wellbeing but it remains unclear how ET modulates their lifetime breast cancer (BC) risk and, if they are diagnosed with BC, how ET affects their BC prognosis. Other groups have established cross-sex hormone treatment mouse models to investigate the impact of gender affirming hormone therapy on bone and cardiovascular health. There is no animal model to investigate the link between cross-sex hormone treatment and cancer. This proposal will develop a cross-sex mouse model of feminization to determine the extent which ET affects BC treatment outcomes. We will transplant three types of breast tumors—Pik3camut, Brca1mut, or Tp53mut—into male mice receiving ET. We will compare tumor growth rates, breast histology, and treatment outcomes between male mice that continue and discontinue ET during BC treatment with alpelisib (for Pik3camut tumors), olaparib (for Brca mut tumors), or eribulin (for Tp53mut tumors). Our long-term goal is to establish BC treatment strategies for the transgender community. Our preclinical model can be utlilized to develop strategies to treat other BC subtypes as well as other hormone- dependent malignancies such as prostate cancer. Our work will not only have implications in reducing transgender cancer disparities; our findings will contribute to our understanding of sex hormone dependencies in BC thus improving treatment strategies for cisgender men and women with BC as well.
项目摘要 本研究的总体目标是建立一种乳腺癌(BC)的跨性别小鼠模型, 为接受雌激素治疗(ET)的跨女性个体制定BC治疗策略。跨女性 个人在出生时被指定为男性,他们中的大多数人追求ET以确认他们的女性身份。 将男性身体长时间暴露在极高的外源性雌激素中, 与顺性别妇女相当的水平引起了人们对ET不良影响的担忧。ET是必不可少的 他们的健康状况,但目前尚不清楚ET如何调节他们一生的乳腺癌(BC)风险,如果他们是 诊断为BC,ET如何影响他们的BC预后。其他研究小组已经建立了跨性别激素 治疗小鼠模型,以研究性别肯定激素治疗对骨和 心血管健康目前还没有动物模型来研究跨性别激素之间的联系 治疗与癌症这项提议将建立一个雌性化的跨性别小鼠模型,以确定 ET影响BC治疗结果的程度。我们将移植三种类型的乳腺肿瘤Pik 3camut, Brca 1 mut或Tp 53 mut-1基因转染ET雄性小鼠。我们将比较肿瘤生长率,乳腺组织学, 在用alpelisib进行BC治疗期间继续和停止ET的雄性小鼠之间的治疗结果 (for Pik 3camut肿瘤)、奥拉帕尼(用于Brca mut肿瘤)或艾日布林(用于Tp 53 mut肿瘤)。我们的长期目标是 为跨性别群体制定BC治疗战略。我们的临床前模型可用于 制定治疗其他BC亚型以及其他激素依赖性恶性肿瘤的策略, 前列腺癌我们的工作不仅对减少跨性别癌症差异有影响, 这些发现将有助于我们理解BC的性激素依赖性,从而改善治疗 为患有BC的顺性别男性和女性制定战略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yu Jing Jan Heng其他文献

Yu Jing Jan Heng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yu Jing Jan Heng', 18)}}的其他基金

Admin Suppl Gender-affirming estrogen therapy and breast cancer treatment outcome
行政补充性别肯定雌激素治疗和乳腺癌治疗结果
  • 批准号:
    10783533
  • 财政年份:
    2023
  • 资助金额:
    $ 24.54万
  • 项目类别:
Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes
性别肯定睾酮疗法对乳腺癌风险和治疗结果的影响
  • 批准号:
    10912193
  • 财政年份:
    2023
  • 资助金额:
    $ 24.54万
  • 项目类别:
Gender-affirming estrogen therapy and breast cancer treatment outcome
性别肯定雌激素治疗和乳腺癌治疗结果
  • 批准号:
    10543116
  • 财政年份:
    2021
  • 资助金额:
    $ 24.54万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 24.54万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 24.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 24.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 24.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 24.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 24.54万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 24.54万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 24.54万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 24.54万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 24.54万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了